TrialJAMA oncology2018

Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.

Chandrajit P Raut et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.